OTCMKTS:LENSF Presbia (LENSF) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 10/21/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Presbia Stock (OTCMKTS:LENSF) Get Presbia alerts:Sign Up Key Stats Today's Range$0.0150▼$0.015050-Day Range$0.0150▼$0.015052-Week Range$0.00▼$0.19VolumeN/AAverage Volume5,650 shsMarket Capitalization$256.80 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Presbia PLC is an Ireland-based medical device company specializing in innovative ophthalmic solutions for presbyopia, the age-related loss of near vision. The company’s lead product, the Presbia Flexivue Microlens, is a precisely engineered corneal inlay designed to be implanted into the corneal stroma. By creating a small permanent refractive change, the lens restores near vision while preserving distance visual acuity through a minimally invasive procedure. Founded in 2006 and headquartered in Dublin, Presbia earned CE mark approval for the Flexivue Microlens in the European Union and commenced commercial sales in select EU markets shortly thereafter. The company has since forged distribution agreements to introduce its technology in Latin America and parts of Asia, working with local partners to expand patient access and surgeon training in its presbyopia treatment. In the United States, Presbia is advancing its clinical program under an investigational device exemption (IDE) to assess safety and efficacy for potential FDA approval. Ongoing research and development efforts focus on refining the surgical delivery system, optimizing lens materials, and broadening patient eligibility criteria to enhance visual outcomes and procedural efficiency. Presbia’s management team combines expertise in medical device development, regulatory affairs and ophthalmic surgery. The company supports its commercial efforts with robust training and educational initiatives for eye-care professionals, aiming to drive adoption of its reversible presbyopia solution and meet the global demand for age-related vision correction.AI Generated. May Contain Errors. Read More Receive LENSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Presbia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENSF Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com LENSF Stock Analysis - Frequently Asked Questions How have LENSF shares performed this year? Presbia's stock was trading at $0.0150 at the start of the year. Since then, LENSF shares have increased by 0.0% and is now trading at $0.0150. How do I buy shares of Presbia? Shares of LENSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:LENSF CIK1591096 Webwww.presbia.com Phone(531) 551-1487Fax323-832-8447Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares17,120,000Free FloatN/AMarket Cap$256.80 thousand OptionableNot Optionable Beta5.91 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:LENSF) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.